Aardvark Therapeutics (NASDAQ:AARD) Raised to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Aardvark Therapeutics from “strong sell” to “sell,” while broader analyst coverage remains mixed; MarketBeat reports a consensus “hold” rating and a $16.30 price target.
• AARD shares opened at $6.54, with a market capitalization of approximately $143.1 million and a 52-week range of $3.35 to $17.94. The stock’s 50-day and 200-day moving averages were $5.65 and $6.49, respectively.
• The clinical-stage biotech reported a quarterly loss of $0.66 per share, beating estimates for a $0.87 loss. Its drug-development programs target RORγ to treat autoimmune and inflammatory diseases such as psoriasis and inflammatory bowel disease.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research report issued to clients and investors on Saturday.

AARD has been the subject of a number of other research reports. BTIG Research cut shares of Aardvark Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, May 15th. HC Wainwright reaffirmed a "neutral" rating and set a $6.00 price objective on shares of Aardvark Therapeutics in a report on Monday, July 20th. Morgan Stanley reiterated an "underweight" rating and issued a $3.00 target price (down from $7.00) on shares of Aardvark Therapeutics in a research report on Friday, May 15th. B. Riley Financial reduced their target price on Aardvark Therapeutics from $8.00 to $7.00 and set a "buy" rating on the stock in a research note on Friday, May 15th. Finally, Weiss Ratings upgraded Aardvark Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, July 2nd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $16.30.

Aardvark Therapeutics Price Performance

Shares of NASDAQ AARD opened at $6.54 on Friday. The stock has a market capitalization of $143.10 million, a PE ratio of -2.04 and a beta of 3.81. Aardvark Therapeutics has a one year low of $3.35 and a one year high of $17.94. The business's fifty day moving average price is $5.65 and its 200-day moving average price is $6.49.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.87) by $0.21. As a group, equities analysts expect that Aardvark Therapeutics will post -3.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Aardvark Therapeutics

A number of large investors have recently added to or reduced their stakes in AARD. Goldman Sachs Group Inc. purchased a new stake in Aardvark Therapeutics during the first quarter valued at about $153,000. Geode Capital Management LLC increased its holdings in shares of Aardvark Therapeutics by 129.7% in the second quarter. Geode Capital Management LLC now owns 136,927 shares of the company's stock worth $1,851,000 after buying an additional 77,327 shares during the period. New York State Common Retirement Fund purchased a new position in shares of Aardvark Therapeutics in the second quarter worth about $99,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Aardvark Therapeutics in the 2nd quarter valued at about $42,000. Finally, Bank of America Corp DE lifted its stake in shares of Aardvark Therapeutics by 72.9% in the 2nd quarter. Bank of America Corp DE now owns 7,989 shares of the company's stock valued at $108,000 after acquiring an additional 3,369 shares during the last quarter.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company's lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source